Tivic Health Systems Inc. has announced a new Amended and Restated Exclusive License Agreement with Statera Biopharma, Inc., which supersedes the previous agreement signed earlier this year. The new agreement maintains similar terms to the original, but introduces key changes, notably allowing Tivic the option to pay royalties in cash or securities. This agreement continues to grant Tivic an exclusive worldwide license to Statera's proprietary Toll-like Receptor 5 agonist program, particularly for Acute Radiation Syndrome, with options for additional indications.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000950170-25-089981), on June 25, 2025, and is solely responsible for the information contained therein.